Sentrimed has prioritized Head and Neck Cancer (HNC) as an initial indication for MASL due to the market size and significant unmet needs. The global HNC therapy market has been estimated at $ 1.7 billion in 2022 and is projected to increase to $ 3 billion by 2030. In the U.S., more than 400,000 individuals have HNC, with 66,000 new cases and nearly 12,000 deaths annually. The five-year overall survival rate is 68% but varies greatly based on stage and location of the tumor. Recurrence occurs in 40% of patients primarily in the first 18 to 24 months with very poor outcomes. Surgery, radiation and/or chemotherapy are the standard of care treatments for oral cancer. Surgery and radiation can be disfiguring and have a significant impact on patients’ quality of life. There are very few approved therapeutic options for HNC and all have limited effectiveness, concerning warnings and precautions, and require intravenous dosing. MASL is currently being studied in an exploratory human signal trial funded by the NIH.